SMAD4 and neoplasm: Many of these mutations involve the KRAS oncogene (90–95% of cases), p16, and TP53 tumor suppressors, SMAD4\DPC4 [17,18], and, more rarely, ARID1A, MLL3, and TGFBR2 [19,20,21].